GF CSI Innovative Drugs Industry ETF (515120) Latest Quoted at RMB 0.62, Net Inflows of RMB 750 Million Over 9 Consecutive Days

NewTimeSpace (newtimespace.com) News, as of 11:16 on September 10, 2026, the CSI Innovative Drugs Industry Index (931152) fell 1.48%, with the GF CSI Innovative Drugs Industry ETF (515120) last quoted at RMB 0.62.

In terms of liquidity, the GF CSI Innovative Drugs Industry ETF recorded an intraday turnover rate of 2.52% and turnover of RMB 282 million. Over a longer horizon, as of September 9, the ETF's average daily turnover over the past month stood at RMB 699 million.

In terms of scale, the ETF's AUM grew by RMB 152 million over the past week, achieving significant growth. (Source: Wind)

In terms of shares, the ETF's latest shares reached 18.157 billion units, hitting a new high for the past month. (Source: Wind)

In terms of fund flows, the ETF has seen net fund inflows for 9 consecutive days, with the highest single-day net inflow at RMB 105 million, totaling RMB 750 million in net inflows ("fund attraction"), and an average daily net inflow of RMB 83.3790 million. (Source: Wind)

Data shows that leveraged funds continue to build positions. The ETF's net margin buy amount on the previous trading day reached RMB 11.4717 million, and its latest margin balance reached RMB 452 million. (Source: Wind)

As of September 9, the ETF's net value had risen 38.18% over the past 2 years. In terms of return capability, as of September 9, 2026, since its inception, the ETF's highest single-month return was 23.00%, its longest winning streak was 5 months, its longest rally gain was 32.68%, and its average return rate in rising months was 5.32%. As of September 9, 2026, the ETF's annualized excess return over the benchmark over the past 3 months was 3.78%.

In terms of drawdown, as of September 9, 2026, the ETF's drawdown relative to the benchmark over the past six months was 0.14%, indicating relatively low drawdown risk among comparable funds. The number of days for recovery after drawdown was 36 days.

In terms of fees, the ETF's management fee rate is 0.50% and its custody fee rate is 0.10%.

In terms of tracking precision, as of September 9, 2026, the ETF's tracking error over the past month was 0.019%, with the highest tracking precision among comparable funds.

In terms of valuation, the CSI Innovative Drugs Industry Index tracked by the GF CSI Innovative Drugs Industry ETF (515120) has a latest price-to-earnings ratio (PE-TTM) of only 42.88x, at the 7.78% percentile over the past year, meaning its valuation is below that of over 92.22% of the time over the past year, placing it at a historic low.

The GF CSI Innovative Drugs Industry ETF (515120) closely tracks the CSI Innovative Drugs Industry Index, which selects no more than 50 of the most representative securities of listed companies whose main business involves innovative drug research and development as its index samples, so as to reflect the overall performance of the securities of listed companies in the innovative drugs industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.